Zhejiang Hisun Pharmaceutical Co., Ltd.

SHSE:600267 Stock Report

Market Cap: CN¥9.6b

Zhejiang Hisun Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Xiao

Chief executive officer

CN¥869.5k

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure5.7yrs
Board average tenureno data

Recent management updates

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

Sep 26
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29
Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

CEO

Kevin Xiao (55 yo)

1.3yrs

Tenure

CN¥869,500

Compensation

Mr. Weihong Xiao, also known as Kevin, has been Chief Executive Officer at Zhejiang Hisun Pharmaceutical Co., Ltd. since October 11, 2023. He served as Chief Operating Officer at 3SBio Inc. since March 201...

Leadership Team

NamePositionTenureCompensationOwnership
Weihong Xiao
Chief Executive Officer1.3yrsCN¥869.50kno data
Hong Shun Jin
Senior Vice President5.7yrsCN¥1.13m0.018%
CN¥ 1.7m
Zhiqing Yang
Senior Vice President5.7yrsCN¥1.39m0.021%
CN¥ 2.0m
Jiaqiu Du
Director and Senior Vice President5.7yrsCN¥2.13m0.021%
CN¥ 2.0m
Xi Fei Shen
Secretary of the Board7.3yrsCN¥825.50k0.013%
CN¥ 1.2m

5.7yrs

Average Tenure

50yo

Average Age

Experienced Management: 600267's management team is seasoned and experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 05:08
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Hisun Pharmaceutical Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jing QiangChina International Capital Corporation Limited
Shanshan LiChina Merchants Securities Co. Ltd.
Ling Bo TuChina Minzu Securities